Sildenafil citrate
| Code | Size | Price |
|---|
| CDX-S0078-M050 | 50 mg | £132.00 |
Quantity:
| CDX-S0078-M250 | 250 mg | £499.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
+20°C
Documents
Further Information
Alternate Names/Synonyms:
5-[2-Ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-4H-pyrazolo[5,4-e]pyrimidin-7-one citrate salt; Actra-Rx; Edegra; Viagra; Tonafil; Apodefil; UK 92480
Appearance:
White to off-white powder.
CAS:
171599-83-0
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07
Handling Advice:
Keep cool and dry.Protect from light and moisture.
Hazards:
H315, H319, H335
InChi:
InChI=1S/C22H30N6O4S.C6H8O7/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28,7-3(8)1-6(13,5(11)12)2-4(9)10/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29),13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
InChiKey:
DEIYFTQMQPDXOT-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 171599-83-0. Formula: C22H30N6O4S . C6H8O7. MW: 474.6 . 192.1. Synthetic. Potent cGMP-specific phosphodiesterase inhibitor that is highly selective for PDE5. It inhibits PDE5 activity in isolated rabbit platelets with an IC50 value of 3.6nM (3nM in human corpus cavernosum) compared to inhibition of PDE1 and PDE3 activities (IC50s = 0.26 and 65µM, respectively). Inhibition of PDE5 enhances the relaxation of smooth muscle in a range of vascular tissues by prolonging the nitric oxide/cGMP-mediated activation of cGMP-dependent protein kinase. While most notable for its use in the treatment of erectile dysfunction, sildenafil?s vasorelaxant properties have also been used to control vascular tone in pulmonary arterial hypertension and high-altitude pulmonary edema associated with altitude sickness. The citrate salt has superior water solubility and pharmacokinetics compared to the base salt of sildenafil.
MDL:
MFCD01632354
Molecular Formula:
C22H30N6O4S . C6H8O7
Molecular Weight:
474.6 . 192.1
Package Type:
Vial
Precautions:
P261, P305, P351, P338
Product Description:
Potent cGMP-specific phosphodiesterase inhibitor that is highly selective for PDE5. It inhibits PDE5 activity in isolated rabbit platelets with an IC50 value of 3.6nM (3nM in human corpus cavernosum) compared to inhibition of PDE1 and PDE3 activities (IC50s = 0.26 and 65µM, respectively). Inhibition of PDE5 enhances the relaxation of smooth muscle in a range of vascular tissues by prolonging the nitric oxide/cGMP-mediated activation of cGMP-dependent protein kinase. While most notable for its use in the treatment of erectile dysfunction, sildenafil?s vasorelaxant properties have also been used to control vascular tone in pulmonary arterial hypertension and high-altitude pulmonary edema associated with altitude sickness. The citrate salt has superior water solubility and pharmacokinetics compared to the base salt of sildenafil.
Purity:
>98% (HPLC)
Signal word:
Warning
SMILES:
OC(=O)CC(O)(CC(O)=O)C(O)=O.CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
Solubility Chemicals:
Soluble in DMSO (20mg/ml).
Source / Host:
Synthetic.
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at +4°C.
References
(1) N.K. Terrett, et al.; Bioorg. Med. Chem. Lett. 6, 1819 (1996) | (2) J. Richalet, et al.; Am. J. Respir. Crit. Care Med. 171, 275 (2005) | (3) C.E. Teixeira, et al.; J. Pharmacol. Exp. Ther. 316, 654 (2006) | (4) S. Jung, et al.; Arch. Pharm. Res. 34, 451 (2011)
Related Products
| Product Name | Product Code | Supplier |
|---|